As a GLP-1 receptor agonist, it not only helps reduce appetite and boosts insulin secretion but also supports substantial weight loss, especially when combined with lifestyle changes
Concomitantly, local hypoxia, oxidative stress, and maladaptive ECM remodeling further exacerbate adipocyte dysfunction, underscoring the multifactorial nature of adipose tissue-driven metabolic derangement in T2DM [18]
Complex carbohydrates high in fibre: Whole grains like quinoa (5g protein and 2.8g fibre per 100g), brown rice, oats, sweet potatoes, legumes like lentils (7.8g fibre per 100g), and chickpeas provide sustained energy and digestive health benefits
Off-Label Use: Some medications are prescribed off-label for weight loss: Semaglutide (Ozempic): FDA-approved for type 2 diabetes (not weight loss) Identical to Wegovy but different indication Commonly prescribed off-label for weight loss Same effectiveness as Wegovy Tirzepatide (Mounjaro): FDA-approved for type 2 diabetes (not weight loss) Identical to Zepbound but different indication Prescribed off-label for weight loss before Zepbound approval Same effectiveness as Zepbound Metformin: Diabetes medication sometimes used for weight loss Produces only 1-3% weight loss Not FDA-approved for weight loss Generally not recommended as primary weight loss medication The Current State of Weight Loss Medication: Clear Winners: GLP-1 receptor agonists (especially tirzepatide and semaglutide) have become the gold standard for medical weight loss, producing results previously unattainable with medication alone
